# Olaparib for PAH: a Multicenter Clinical Trial

> **NCT03782818** · PHASE1,PHASE2 · TERMINATED · sponsor: **Laval University** · enrollment: 17 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT03782818
- **Lead sponsor:** Laval University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-20
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-10-31
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** The recruitment was stopped on October 31st 2024 due to limited recruitment within the last year, as well as the end of funding (Spring 2025).
- **Last updated:** 2025-02-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03782818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03782818, "Olaparib for PAH: a Multicenter Clinical Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03782818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*